Anthropic’s claim its AI agents discovered an unusual pattern in viral DNA similar to what’s seen in the gene-editing tool CRISPR Cas-9 has set off controversy.

Scientists used CRISPR/Cas9 to disrupt the tyr and oca2 pigmentation genes in zebrafish, reducing melanophores and visibly ...

CRISPR Therapeutics appointed Andrew J. Silver as Chief Financial Officer and principal financial officer on October 19, 2026 ...

Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, ...

Spread the loveImagine looking in the mirror and seeing a younger version of yourself, not just cosmetically, but at a ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.89, moving 1.21% from the previous trading session.

- CRISPR Therapeutics' $53 stock price remains volatile ahead of November 9's pivotal CTX310 gene-editing data release for hypertriglyceridemia. - Technical indicators show the stock pinned between ...

Spread the loveImagine turning back the clock, not on your watch, but on your very own cells. It sounds like something ...

ERS Genomics Limited ('ERS Genomics'), the CRISPR licensing company, today announced that it has signed a non-exclusive ...

A 2026 review summarizes advances in CRISPR-Cas9 precision, delivery and primary-cell engineering for genetic diseases and ...

CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related ...